John G Curd

Title: The Innovative Contributions of John G Curd

Introduction

John G Curd is a notable inventor based in Burlingame, California. He has made significant strides in the field of cancer treatment through his innovative work. His research focuses on the use of hypoxia-activated prodrugs, which have the potential to revolutionize cancer therapy.

Latest Patents

John G Curd holds a patent for the treatment of cancer using hypoxia-activated prodrugs. This patent outlines a method where cancer can be treated by administering a hypoxia-activated prodrug, such as TH-302, either alone or in combination with other anticancer agents and/or radiation therapy. The patent emphasizes that in combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period. Furthermore, the administration of the hypoxia-activated prodrug may be completed prior to beginning the administration of the other anticancer agent or radiation therapy.

Career Highlights

Throughout his career, John G Curd has worked with several prominent companies in the biotechnology sector. Notably, he has been associated with Threshold Pharmaceuticals, Inc. and Immunogenesis, Inc. His work in these organizations has contributed to advancements in cancer treatment methodologies.

Collaborations

John G Curd has collaborated with several professionals in his field, including Stewart Kroll and Mark D Matteucci. These collaborations have further enhanced his research and development efforts in cancer therapies.

Conclusion

John G Curd's innovative contributions to cancer treatment through hypoxia-activated prodrugs highlight his significant role in the field of medical research. His work continues to inspire advancements in cancer therapy and offers hope for improved treatment options.